PCNA-I1
|
PCNA-I1
|
444930-42-1
|
EG1
|
2-(4-(2-甲氧基苯甲酰氨基)苯甲酰氨基)苯甲酸
|
693241-54-2
|
CID44216842
|
KUC103479N-02
|
1222513-26-9
|
MLS-573151
|
MLS-573151
|
10179-57-4
|
BAY-1797
|
BAY-1797
|
2055602-83-8
|
AGX51
|
N-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-N-benzylpropanamide
|
330834-54-3
|
NG-25
|
N-[4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-4-甲基-3-(1H-吡咯并[2,3-B]吡啶-4-基氧基)苯甲酰胺
|
1315355-93-1
|
CHD1Li 6.11
|
化合物 CHD1LI 6.11
|
2716890-91-2
|
DS18561882
|
DS18561882
|
2227149-22-4
|
AST487
|
AST 487
|
630124-46-8
|
Cedirogant
|
4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]-
|
2055496-11-0
|
SR9238
|
1416153-62-2
|
1416153-62-2
|
VY-3-135
|
化合物VY-3-135
|
|
BAY-218
|
CPD3504
|
2162982-11-6
|
Dalpiciclib free base
|
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]-
|
1637781-04-4
|
Bromosporine
|
C17H20N6O4S
|
1619994-69-2
|
Grp94inhibitor-1
|
GRP94
|
2234897-35-7
|
YKL 06-061
|
YKL 06-061
|
2172617-15-9
|
NEO2734 (EP31670)
|
化合物NEO2734
|
2081072-29-7
|
PLX51107
|
化合物PLX51107
|
1627929-55-8
|
UNC-1215
|
UNC1215
|
1415800-43-9
|
Toceranib
|
Toceranib
|
356068-94-5
|
Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1)
|
Opiranserin鹽酸鹽
|
1440796-75-7
|
4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl
|
泊馬度胺 4'-PEG1-胺
|
2154342-56-8
|
FIPI
|
FIPI
|
939055-18-2
|
Laquinimod
|
拉喹莫德
|
248281-84-7
|
GSK854
|
3-((6-((5-chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide
|
1316059-00-3
|
Mibampator(LY451395)
|
MIBAMPATOR
|
375345-95-2
|
(S)-6-(4-chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide
|
AHR antagonist 3
|
2242464-44-2
|
3-Pyridinecarboxylic acid, 5-bromo-
|
5-溴煙酸
|
20826-04-4
|
LMI070
|
化合物LMI 070
|
1562338-42-4
|
tasquinimod
|
他喹莫德
|
254964-60-8
|
2-[2-(quinolin-3-yl)pyridin-4-yl]-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
|
2-[2-(3-quinolyl)-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
|
724711-21-1
|
CASIN
|
CASIN
|
425399-05-9
|
RIPA-56
|
RIPA-56
|
1956370-21-0
|
HS-1371
|
HS1371
|
2158197-70-5
|
PF-5274857
|
PF-5274857
|
1373615-35-0
|
K-756
|
130017-40-2
|
130017-40-2
|
SBI-797812
|
SBI-797812
|
2237268-08-3
|
NK-252
|
1414963-82-8
|
1414963-82-8
|
4E2RCat
|
432499-63-3
|
432499-63-3
|
N-ETHYL-2-[(6-METHOXYPYRIDIN-3-YL)-(2-METHYLPHENYL)SULFONYLAMINO]-N-(PYRIDIN-3-YLMETHYL)ACETAMIDE
|
N-ETHYL-2-[(6-METHOXYPYRIDIN-3-YL)-(2-METHYLPHENYL)SULFONYLAMINO]-N-(PYRIDIN-3-YLMETHYL)ACETAMIDE
|
680590-49-2
|
GSK583
|
6-(叔丁基磺?;?-N-(5-氟-1H-吲唑-3-基)喹啉-4-胺
|
1346547-00-9
|
APD668
|
APD668
|
832714-46-2
|
Palosuran
|
ACT 058362; PALOSURAN,
|
540769-28-6
|
SK2033
|
GSK 2033
|
1221277-90-2
|
PFI-1
|
PFI-1 (PF-6405761)
|
1403764-72-6
|
BRD4-IN-1 ( FL411 )
|
2-(4-羥基-3,5-二甲基苯基)-7-甲基-5,6,7,8-四氫吡啶并[4',3':4,5]噻吩并[2,3-D]嘧啶-4(1H)-酮
|
2118944-88-8
|
SR18662
|
(E)-3-(3,4-dichlorophenyl)-N-(2-(4-(methylsulfonyl)piperazin-1-yl)-2-oxoethyl)acrylamide
|
2505001-62-5
|
SR15006
|
SR 15006
|
2505001-54-5
|
BMS-833923
|
BMS-833923
|
1059734-66-5
|
Tigulixostat
|
化合物 TIGULIXOSTAT
|
1287766-55-5
|
A-443654
|
(ALPHAS)-ALPHA-[[[5-(3-甲基-1H-吲唑-5-基)-3-吡啶基]氧基]甲基]-(S)-1H-吲哚-3-乙胺
|
552325-16-3
|
DUN61488
|
ONC212
|
1807861-48-8
|
PHT-427
|
4-十二烷基-N-1,3,4-噻二唑-2-基苯磺酰胺
|
1191951-57-1
|
DY 268
|
DY 268
|
1609564-75-1
|
V-9302
|
V-9302
|
1855871-76-9
|
Ezatiostat
|
EZATIOSTAT游離的
|
168682-53-9
|
LDN-193189 (DM3189) 2HCl
|
LDN-193189 2HCL
|
1435934-00-1
|
TAK-901
|
5-[3-(乙基磺酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-B]吲哚-7-甲酰胺
|
934541-31-8
|
Perospirone
|
哌羅匹隆
|
150915-41-6
|
SR-2211
|
2-Fluoro-4'-[[4-(4-pyridinylMethyl)-1-piperazinyl]Methyl]-偽,偽-bis(trifluoroMethyl)-[1,1'-biphenyl]-4-Methanol
|
1359164-11-6
|
Teijin compound 1
|
化合物 T19230
|
1313730-14-1
|
PIK-93
|
N-[5-[4-氯-3-[[(2-羥基乙基)氨基]磺?;鵠苯基]-4-甲基-2-噻唑基]乙酰胺
|
593960-11-3
|
SB 657510
|
2-溴-N-[4-氯-3-[[(3R)-1-甲基-3-吡咯烷基]氧基]苯基]-4,5-二甲氧基-苯磺酰胺
|
474960-44-6
|
Sivelestat (ONO5046, LY544349, EI546)
|
西維來司他
|
127373-66-4
|
UNC0379
|
UNC0379
|
1620401-82-2
|
SR10067
|
3-[[4-(1,1-Dimethylethoxy)phenoxy]methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-1-naphthalenylmethanone
|
1380548-02-6
|
FGTI-2734
|
FGTI-2734
|
1247018-19-4
|
Ulixacaltamide (Z944)
|
N-((1-(2-(叔丁基氨基)-2-氧代乙基)哌啶-4-基)甲基)-3-氯-5-氟苯甲酰胺
|
1199236-64-0
|
SYP-5
|
1384268-04-5
|
1384268-04-5
|
WS6
|
WS6
|
1421227-53-3
|
ZINC00881524
|
557782-81-7
|
557782-81-7
|
Sulfatinib
|
5-羥基-2-甲基吲哚
|
1308672-74-3
|
LP-935509
|
化合物LP-935509
|
1454555-29-3
|
Dacinostat
|
達諾司他
|
404951-53-7
|
STF-62247
|
N-(3-甲基苯基)-4-(4-吡啶)-2-噻唑胺
|
315702-99-9
|
JC124
|
Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]-
|
1638611-48-9
|
Dovramilast
|
化合物 DOVRAMILAST
|
340019-69-4
|
NVP-BHG712
|
4-甲基-3-[[1-甲基-6-(3-吡啶基)-1H-吡唑并[3,4-D]嘧啶-4-基]氨基]-N-[3-(三氟甲基)苯基]苯甲酰胺
|
940310-85-0
|
NVP-BVU 972
|
6-[[6-(1-甲基-1H-吡唑-4-基)咪唑并[1,2-B]噠嗪-3-基]甲基]喹啉
|
1185763-69-2
|
AZ960
|
5-氟-2-[[(1S)-1-(4-氟苯基)乙基]氨基]-6-[(5-甲基-1H-吡唑-3-基)氨基]-3-吡啶腈
|
905586-69-8
|
H3B-120
|
H3B-120
|
2194903-42-7
|
KHS101 hydrochloride
|
鹽酸KHS101
|
1784282-12-7
|
Benzenesulfonamide, 3,4-dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-
|
RO 61-8048
|
199666-03-0
|
WQ 1
|
化合物Σ1 RECEPTOR ANTAGONIST-1
|
1204401-49-9
|
BCI-121
|
BCI-121
|
432529-82-3
|
IWP-L6
|
IWP-L6
|
1427782-89-5
|
M4205
|
化合物M4205
|
2590556-80-0
|
Lofepramine
|
洛非帕明
|
23047-25-8
|
Mebeverine Acid
|
美貝維林 鹽酸鹽
|
475203-77-1
|
CCR6 inhibitor 1
|
2-Pyridinecarboxamide, 4-[4-[[trans-4-[[5-(trifluoromethyl)-2-pyridinyl]amino]cyclohexyl]sulfonyl]phenyl]-
|
2437547-04-9
|
ATC 0175 hydrochloride
|
ATC 0175
|
510733-97-8
|
Ceapin-A7
|
N-(1-(2,4-雙(三氟甲基)芐基)-1H-吡唑-4-基)-5-(呋喃-2-基)異惡唑-3-甲酰胺
|
2323027-38-7
|
MCP110
|
化合物 T24437
|
521310-51-0
|
GNE-9815
|
化合物GNE-9815
|
2729996-45-4
|
SB 218795
|
化合物 T23316
|
174635-53-1
|
CC-90010
|
CC-90010
|
1706738-98-8
|
BAY-179
|
化合物BAY-179
|
|
Bevenopran
|
676500-67-7
|
676500-67-7
|